Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VICTORIA A STATLER

Allopathic & Osteopathic Physicians Pediatrics Pediatric Infectious Diseases

NPI
1770604191
CMS profile
1239227
Location
LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,241.86

10 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $805.34 3
Food and Beverage $436.52 7

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $1,241.86 10

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VICTORIA A STATLER

NPI 1770604191 · CMS profile ID 1239227

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Infectious Diseases

LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1770604191?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VICTORIA A STATLER, NPI 1770604191, CMS profile ID 1239227. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770604191?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). VICTORIA A STATLER, NPI 1770604191, CMS profile ID 1239227. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770604191?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
VICTORIA A STATLER, NPI 1770604191, CMS profile ID 1239227, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–10 of 10 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1770604191?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

10 matching records · $1,241.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 10 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–10 of 10.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $11.7112/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238031016 CMS
Merck Sharp & Dohme LLC $40.0012/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238037122 CMS
Merck Sharp & Dohme LLC $64.9212/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238006288 CMS
Merck Sharp & Dohme LLC $60.0012/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238029092 CMS
Merck Sharp & Dohme LLC $54.9912/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238036802 CMS
Merck Sharp & Dohme LLC $30.0012/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238028884 CMS
Merck Sharp & Dohme LLC $64.9212/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238028886 CMS
Merck Sharp & Dohme LLC $473.9612/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238036116 CMS
Merck Sharp & Dohme LLC $149.9812/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238037572 CMS
Merck Sharp & Dohme LLC $291.3812/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238039048 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $485.74 1
PY2021 $5,500.00 2
PY2022 $2,450.00 5
PY2023 $2,162.77 4
PY2024 $4,326.00 2
PY2025 $1,241.86 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $89,965.23 2
PY2024 Principal investigator $56,359.42 4
PY2023 Principal investigator $17,015.00 3
PY2022 Principal investigator $28,796.43 7
PY2021 Recipient $198.26 2
PY2021 Principal investigator $33,032.43 42
PY2020 Recipient $2,869.17 11
PY2020 Principal investigator $78,870.85 49
PY2019 Recipient $537.78 2
PY2019 Principal investigator $83,019.90 45

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Gilead Sciences, Inc. $2,370.00 12/23/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Infection Trials No dispute reported 06/30/2026 742084333
Principal investigator 1 SANOFI PASTEUR INC. $1,500.00 12/15/2020 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744036427
Recipient Astellas Pharma Global Development $59.83 12/10/2020 Covered Recipient Physician A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients No dispute reported 06/30/2026 721319973
Principal investigator 1 SANOFI PASTEUR INC. $2,160.00 11/19/2020 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744036369
Recipient Astellas Pharma Global Development $129.57 10/22/2020 Covered Recipient Physician A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients No dispute reported 06/30/2026 721319971
Principal investigator 1 SANOFI PASTEUR INC. $2,840.00 10/20/2020 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744036323
Principal investigator 1 Gilead Sciences, Inc. $750.00 10/19/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Infection Trials No dispute reported 06/30/2026 742084331
Principal investigator 1 SANOFI PASTEUR INC. $1,520.00 09/22/2020 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744036297
Recipient Astellas Pharma Global Development $199.43 09/18/2020 Covered Recipient Physician A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients No dispute reported 06/30/2026 721319969
Principal investigator 1 SANOFI PASTEUR INC. $5,900.00 08/20/2020 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744036285
Principal investigator 1 Gilead Sciences, Inc. $2,835.00 08/05/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Infection Trials No dispute reported 06/30/2026 742084329
Principal investigator 1 SANOFI PASTEUR INC. $5,220.00 07/21/2020 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744036261
Recipient Astellas US Technologies $315.39 06/24/2020 Covered Recipient Physician A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709602949
Recipient Astellas US Technologies $315.39 06/24/2020 Covered Recipient Physician A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709602955
Recipient Astellas US Technologies $315.39 06/24/2020 Covered Recipient Physician A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709602957
Recipient Astellas US Technologies $315.39 06/24/2020 Covered Recipient Physician A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709602961
Recipient Astellas US Technologies $315.39 06/24/2020 Covered Recipient Physician A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709602965
Recipient Astellas US Technologies $315.39 06/24/2020 Covered Recipient Physician A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709602969
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604675
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604679
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604683
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604687
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604689
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604693
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604695
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604699
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604703
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604707
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604711
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604713
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604717
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604719
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604723
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604727
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604731
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604735
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604737
Principal investigator 1 Astellas US Technologies $315.39 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE
A PHASE 2, OPEN-LABEL, NON-COMPARATIVE, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF ISAVUCONAZONIUM SULFATE FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS (IA) OR INVASIVE MUCORMYCOSIS (IM) IN PEDIATRIC SUBJECTS No dispute reported 06/30/2026 709604741
Principal investigator 1 SANOFI PASTEUR INC. $2,600.00 06/18/2020 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744036221
Principal investigator 1 Gilead Sciences, Inc. $1,896.00 06/17/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Infection Trials No dispute reported 06/30/2026 742084327
Principal investigator 1 Astellas Pharma Global Development $1,500.00 05/12/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients No dispute reported 06/30/2026 721321921
Principal investigator 1 SANOFI PASTEUR INC. $2,490.00 05/07/2020 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744036197
Recipient Astellas Pharma Global Development $399.00 04/30/2020 Covered Recipient Physician A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients No dispute reported 06/30/2026 757848080
Principal investigator 1 SANOFI PASTEUR INC. $970.00 04/21/2020 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744036187
Principal investigator 1 Gilead Sciences, Inc. $378.00 04/20/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Infection Trials No dispute reported 06/30/2026 742084325
Recipient Astellas Pharma Global Development $189.00 04/18/2020 Covered Recipient Physician A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients No dispute reported 06/30/2026 757848078
Principal investigator 1 Gilead Sciences, Inc. $10,143.00 03/18/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection No dispute reported 06/30/2026 742084323
Principal investigator 1 SANOFI PASTEUR INC. $5,910.00 03/17/2020 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744036173
Principal investigator 1 SANOFI PASTEUR INC. $1,164.75 03/03/2020 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744036151
Principal investigator 1 SANOFI PASTEUR INC. $442.00 03/03/2020 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744036163
Principal investigator 1 Merck Sharp & Dohme Corporation $428.40 03/02/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 740782935
Principal investigator 1 Merck Sharp & Dohme Corporation $428.40 03/02/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 740782937
Principal investigator 1 SANOFI PASTEUR INC. $442.00 02/13/2020 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744036115
Principal investigator 1 SANOFI PASTEUR INC. $4,850.00 02/13/2020 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744036123
Principal investigator 1 Gilead Sciences, Inc. $2,835.00 02/05/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection No dispute reported 06/30/2026 742084321
Principal investigator 1 Gilead Sciences, Inc. $378.00 01/27/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Infection Trials No dispute reported 06/30/2026 742084315
Principal investigator 1 Gilead Sciences, Inc. $1,624.00 01/27/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection No dispute reported 06/30/2026 742084317
Principal investigator 1 Gilead Sciences, Inc. $1,896.00 01/27/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION
A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Infection Trials No dispute reported 06/30/2026 742084319
Principal investigator 1 SANOFI PASTEUR INC. $5,380.00 01/14/2020 Non-covered Recipient Entity
University Of Louisville Hospital
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 744036097
Principal investigator 1 Astellas Pharma Global Development $1,712.50 01/09/2020 Non-covered Recipient Entity
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients No dispute reported 06/30/2026 721320995